DYAI customers relationship map

Dyadic (DYAI) — customer relationships that drive near-term commercialization

Dyadic monetizes a proprietary microbial protein production platform (C1) by licensing technology, performing R&D services, taking milestone payments and equity, entering profit‑share and OEM distribution deals, and collecting royalties on commercialized recombinant proteins and enzymes. Revenue is concentrated and partnership-driven: the company converts platform IP into commercial sales through third‑party manufacturers and distributors rather than large in‑house volume manufacturing. For a deeper look at partner-derived revenue signals, visit https://nullexposure.com/ for the full analytical framework.

Quick financial and commercial snapshot for investors

Dyadic is a small‑cap biotechnology firm with TTM revenue of $3.09M and negative EPS (-$0.22), and its cash generation is currently dependent on partner milestones and early commercial receipts rather than broad end‑market penetration. Customer concentration is material: two customers accounted for roughly 54.8% of revenue in FY2024, and international customers (EMEA/APAC) represent a meaningful portion of sales. Market capitalization (~$27.4M) and limited institutional ownership underscore the company’s early commercial stage and partnership-driven go‑to‑market model.

How Dyadic structures commercial relationships

Dyadic’s contracts are predominantly licensing and long‑term agreements, combined with service and development arrangements that include upfront fees, milestone payments, profit‑share and royalty mechanics. The company positions itself as licensor and development service provider—retaining IP control while outsourcing global sales and scale manufacturing through third parties. This model generates recurring cash inflections tied to milestones and commercialization events rather than steady product sales from Dyadic’s own balance sheet.

Customer and partner map — what each relationship contributes

Below are concise, sourced summaries for every customer and partner referenced in Dyadic’s public materials.

Inzymes

Dyadic has an active license and collaboration with Inzymes that generated license revenue in FY2024 and includes milestone mechanics tied to productivity achievements and commercialization. According to Dyadic’s FY2024 disclosures and subsequent press releases (GlobeNewswire, March 2, 2026), the partnership targets commercialization of non‑animal bovine chymosin in 2026.

Janssen

Dyadic executed a license agreement with Janssen that produced license revenue in FY2023 and included upfront payment provisions for using the C1 platform. This arrangement is documented in Dyadic’s 2024 Form 10‑K and in a 2021 GlobeNewswire release announcing the research license with Janssen Biotech (FY2021).

Proliant

Proliant (variant spellings in Dyadic disclosures) is a strategic development and commercialization partner for recombinant serum albumin; Dyadic recognized milestone receipts and expects profit‑share as Proliant commercializes the product. The Proliant Agreement and related milestone receipts are disclosed in Dyadic’s 2024 10‑K and multiple press releases (GlobeNewswire and earnings call transcripts, FY2024–FY2026).

Fermbox Bio

Fermbox Bio purchased enzyme product and collaborates with Dyadic on an enzyme cocktail to convert agricultural residues into fermentable sugars; Dyadic reported initial enzyme delivery after a purchase order in FY2025. This progress is cited in Dyadic’s Q2 2025 results and the Q3 2025 earnings call.

Opes Diagnostics Limited

Dyadic entered a commercial agreement with Opes to support launch and distribution of recombinant transferrins and FGFs for serum‑free cell culture applications; the deal is positioned to accelerate market adoption. GlobeNewswire reported this agreement in December 2025 (FY2025).

Proliant Health & Biologicals / Proliant Health and Biologicals / ProLiant Health and Biologics / ProLiant / PLHE

Dyadic references multiple Proliant name variants across filings and press releases because the relationship spans development, commercialization, milestone payments and a profit‑sharing arrangement for recombinant albumin. Dyadic documented receipt of milestone payments (totaling $1.0M and later $1.5M by FY2025) and expects ongoing profit‑share as Proliant leverages established sales channels (GlobeNewswire; Q2 and Q3 2025 releases; earnings call transcripts, FY2025–FY2026).

IBT Bioservices (Integrated Biotherapeutics, LLC d/b/a IBT Bioservices)

Dyadic executed an OEM distribution agreement with IBT to enable distribution of recombinant proteins through IBT’s global reagent channels, expanding Dyadic’s commercial footprint for research reagents. GlobeNewswire announced this OEM distribution partnership in March 2026 (FY2026).

Rabian BV

Rabian will develop a rabies vaccine using Dyadic’s C1 platform under a funded collaboration that grants Dyadic equity and milestone/royalty upside upon commercialization. This strategic partnership and the ~€1.7M funding commitment are described in Dyadic press materials (GlobeNewswire, FY2024–FY2026).

Incyte (INCY)

Dyadic disclosed a partnership with Incyte to commercialize recombinant bovine chymosin, structured with upfront access fees, milestone payments and potential royalties, targeting a 2026 launch. The Incyte arrangement was highlighted in the Q4 2025 earnings call transcript (reported FY2026).

IVT BioServices

Dyadic announced an OEM distribution agreement with IVT BioServices to distribute animal‑free recombinant products (including DNase I and transferrin) through IVT’s channels, reinforcing Dyadic’s channel‑based commercialization strategy. This was disclosed in an earnings call transcript covering late 2025/FY2026.

Phibro Animal Health / Phibro Animal Health/Abic Biological Laboratories Ltd / Abic Biological Laboratories

Dyadic maintains collaborative and sublicense relationships in the animal health/vaccine space, including an R&D agreement and sub‑license arrangements with Phibro/Abic to develop livestock vaccines and treatments. These arrangements are described in investor summaries and company disclosures (SimplyWall.st summary, FY2024–FY2025; GlobeNewswire FY2024).

Janssen Biotech, Inc. / JNJ

Dyadic’s 2021 research license with Janssen Biotech included a $500,000 upfront for non‑exclusive rights to the C1 platform; the Janssen engagement is a precedent for larger pharma collaborations. GlobeNewswire announced the Janssen agreement in FY2021 and Dyadic references Janssen in the FY2024 10‑K.

Inzymes ApS

A March 2026 GlobeNewswire release states Dyadic and Denmark‑based Inzymes ApS planned commercialization of recombinant non‑animal bovine chymosin in 2026 following final development milestones. The statement frames Inzymes ApS as the commercialization partner for dairy enzyme applications (FY2026).

RigBio

Dyadic agreed with RigBio to develop and commercialize animal‑free recombinant bovine alpha‑lactalbumin for health and nutrition markets, positioning Dyadic for protein launches beyond lab reagents. This was discussed in the Q4 2025 earnings call transcript (reported FY2026).

Reliant Health and Biologics

Dyadic cited a partnership with Reliant advancing recombinant human albumin toward commercial launch in early 2026, reflecting multiple co‑development/commercialization arrangements across albumin programs. This point comes from earnings call reporting in FY2025.

Vaccine and Immunotherapy Center at Massachusetts General Hospital

Dyadic delivered a C1‑produced H1N1 influenza antigen in a fully funded research collaboration with MGH’s Vaccine and Immunotherapy Center, demonstrating C1’s applicability to vaccine antigen production. Dyadic announced this result in Q2 2024 investor communications (GlobeNewswire, FY2024).

Rubic One Health

Dyadic holds a license agreement with Rubic One Health to develop livestock vaccines as part of its animal health partnerships; the relationship is referenced in investor summaries (SimplyWall.st, FY2025).

Operational constraints that define the business model

Contracting posture: Dyadic’s revenue mix is dominated by licensing and long‑term agreements that include upfront fees, milestones and royalties rather than spot product sales. Evidence in the 2024 10‑K shows sublicensing and license revenue as core sources.
Concentration and commercial criticality: Material customer concentration (two customers >50% of revenue in FY2024) creates near‑term cash sensitivity to partner milestones and commercialization timing.
Geographic footprint: Dyadic operates in the U.S. and Europe and generates sizeable international revenue (EMEA and APAC exposures are material), which distributes commercial risk but introduces cross‑jurisdiction execution complexity.
Role and revenue recognition: Dyadic functions as both licensor and service provider, recognizing research revenue and milestone receipts under ASC 606—this structure produces lumpy, event‑driven cash inflows.
Segment focus and maturity: The business is managed as a single operating segment focused on core synthetic protein products (C1 and Dapibus platforms), with many partnerships still in early commercialization stages.

Investment implications — what to watch next

Catalysts: first‑commercial sales and recurring profit‑share receipts from Proliant/ProLiant launches, commercial distribution ramps via IBT/IVT, and milestone realization from Inzymes/Incyte programs.
Risks: revenue concentration, reliance on partner commercialization execution, and the staging of multiple product launches across partners.
For a systematic analysis of partner exposure and event timing, review our research portal at https://nullexposure.com/.

Bold strategic partnerships and milestone cadence will determine whether Dyadic’s IP monetization model delivers scalable cash flow or remains lumpy near‑term; investors should track each partner’s commercialization milestones and initial revenue recognition events.

DYAI customer relationships